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Mdm2 controls CREB-dependent transactivation and
initiation of adipocyte differentiation
P Hallenborg1,2, S Feddersen1, S Francoz3, I Murano4, U Sundekilde1, RK Petersen2, V Akimov1, MV Olson5, G Lozano5, S Cinti4,
BT Gjertsen6, L Madsen2,7, J-C Marine3, B Blagoev1 and K Kristiansen*,2
The role of the E3 ubiquitin ligase murine double minute 2 (Mdm2) in regulating the stability of the p53 tumor suppressor is well
documented. By contrast, relatively little is known about p53-independent activities of Mdm2 and the role of Mdm2 in cellular
differentiation. Here we report a novel role for Mdm2 in the initiation of adipocyte differentiation that is independent of its ability
to regulate p53. We show that Mdm2 is required for cAMP-mediated induction of CCAAT/enhancer-binding protein d (C/EBPd)
expression by facilitating recruitment of the cAMP regulatory element-binding protein (CREB) coactivator, CREB-regulated
transcription coactivator (Crtc2)/TORC2, to the c/ebpd promoter. Our findings reveal an unexpected role for Mdm2 in the
regulation of CREB-dependent transactivation during the initiation of adipogenesis. As Mdm2 is able to promote adipogenesis in
the myoblast cell line C2C12, it is conceivable that Mdm2 acts as a switch in cell fate determination.
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Adipocytes originate from mesenchymal stem cells (MSCs)
that also are precursors for muscle and bone cells. Studies of
preadipocyte cell lines and embryonic fibroblasts have
delineated a transcriptional cascade involving peroxisome
proliferator-activated receptor g (PPARg) and three members
of the CCAAT/enhancer-binding protein (C/EBP) family –
C/EBPd, C/EBPb and C/EBPa – that are activated sequen-
tially during adipogenesis.1
C/EBPb and C/EBPd are induced early and transiently
during differentiation and are considered to play key roles
during the initiation of the adipogenic program. The two
C/EBPs act in concert with overlapping, but not identical,
activities as indicated by the more severe adipose
phenotype of mice lacking both C/EBPb and C/EBPd than
that of mice lacking either of the two C/EBPs.2 Activation of
C/EBPb and C/EBPd leads to the induction of C/EBPa and
PPARg expression orchestrating terminal adipocyte differen-
tiation.3
Besides PPARg and the three C/EBPs, other transcription
factors are reported to be required for adipocyte differentiation.
Activation of the cAMP regulatory element-binding protein
(CREB) at the onset of adipocyte differentiation is critical for
adipogenesis.4–6 The recent cloning and characterization of a
CREB cofactor family, denoted as CREB-regulated transcrip-
tion coactivator (Crtc/TORC), have revealed how CREB can
induce expression of distinct target genes dependent on
different stimuli.7–9
The murine double minute 2 (Mdm2) is an E3 ubiquitin
ligase with oncogenic properties. Its importance in the control
of p53 activity is underscored by the finding that knockout of
p53 rescues the embryonic lethality of mice lacking
mdm2.10,11 Deregulation of p53 activity in embryos lacking
mdm2 leads to widespread apoptosis and ensuing embryonic
death.12 Although Mdm2 plays a critical role in the regulation
of p53 signaling, an increasing body of evidence indicates that
Mdm2 may exert p53-independent functions.13
Amplification of themdm2 gene occurs in 10% of all human
cancers.14 Interestingly, mdm2 is amplified in nearly all
liposarcomas.15 As the genetic aberration in a malignant
transformation of an MSC was recently suggested to regulate
the differentiation of the transformed cells,16 the high
prevalence of mdm2 amplification in liposarcomas could
indicate an involvement of mdm2 in adipogenesis. Further-
more, the mdm2 gene is amplified in the widely used
preadipocyte cell line, 3T3-L1.17 Still, the functional conse-
quence of its amplification and the role of Mdm2 in
adipogenesis have not been elucidated. Here we show that
Mdm2 regulates adipogenesis by promoting cAMP-mediated
transcriptional activation of CREB and induction of C/EBPd
expression by facilitating the recruitment of Crtc2 to a
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cAMP-response element (CRE) in the promoter of c/ebpd.
Our unexpected findings identify Mdm2 as a novel critical
player in the intricate network of factors that regulate CREB-
dependent transactivation and adipocyte differentiation.
Results
Mdm2 is required for adipogenesis ex vivo. The 3T3-L1
preadipocyte cell line and mouse embryonic fibroblasts
(MEFs) have been instrumental for studying adipocyte
differentiation. Although MEFs lacking Mdm2 cannot be
established owing to the early embryonic lethality,12 MEFs
deficient for both p53 and Mdm2 can be obtained.10,11
When treating p53/ and p53/;mdm2/ MEFs with a
standard hormonal cocktail (MDI) containing the cAMP-
elevating compound, 3-isobutyl-1-methylxanthine (IBMX),
the glucocorticoid receptor agonist, dexamethasone (Dex)
and insulin (Ins) commonly used for the induction of adipocyte
differentiation, we observed a dramatic reduction in the
adipogenic potential of p53/;mdm2/ MEFs compared
with p53/ MEFs as visualized by Oil-Red-O staining
of triglycerides and marker gene expression (Figure 1a).
Inclusion of the potent PPARg ligand rosiglitazone during
differentiation did not restore differentiation of p53/;mdm2/
MEFs (Figure 1b).
To establish a causal link between lack of Mdm2 and
impaired adipogenesis, we attempted to rescue adipogenesis
by restoring Mdm2 expression using retroviral transduction of
p53/;mdm2/ MEFs. In accordance with a previous
report,18 cells expressing full-length Mdm2 did undergo cell
cycle arrest (data not shown). This presumably relates to the
use of the cDNA of mdm2 for retroviral expression, as
overexpression of Mdm2 using a genomic clone harboring the
entire mdm2 gene results in cell transformation.19
To circumvent the cell cycle arrest imposed by expressing
full-length mdm2 cDNA, we retrovirally expressed different
portions of Mdm2 (Mdm2 aa 1–220 and Mdm2 aa 221–491)
separately (Figures 1c and d). P53/;mdm2/ MEFs
expressing the N-terminal half of Mdm2 (Mdm2 aa 1–220)
underwent adipocyte differentiation, whereas MEFs trans-
duced with either empty vector or vector encoding Mdm2 aa
221–491 did not. Ectopic expression of full-length MdmX
(or Mdm4), a protein that is structurally and functionally
related to Mdm2, failed to restore adipogenesis in the p53/;
mdm2/ MEFs (Supplementary Figure 1).
Collectively, these results indicate that Mdm2 regulates
adipocyte differentiation, independent of its ubiquitin ligase
activity and its ability to control p53 activity.
In an attempt to obtain evidence for the possible involve-
ment of Mdm2 in adipogenesis in an in vivo setting, we used
CT scanning to compare the amount of adipose tissue in mice
harboring a missense mutation in p53 (p53H/H)20 with mice
having mutated p53 and lacking mdm2 (p53H/Hmdm2/).
Only a limited number of p53H/H and p53H/Hmdm2/ mice
were available (n¼ 4 and 5, respectively). However, loss of
Mdm2 did not affect bone mass, soft tissue and total adipose
tissue (P40.05) (Figure 1e), indicating that loss of Mdm2
in vivo may at least in part be counteracted by compensatory
regulatory pathways.
Mdm2 promotes a switch from myogenesis to adipo-
genesis ex vivo. Adipocytes and myocytes are both derived
from MSCs. Interestingly, in p53/;mdm2/ MEFs induced
to undergo adipocyte differentiation we observed the
sporadic appearance of cells morphologically resembling
myocytes (Figure 2a). Such cells were not seen in p53/
MEF cultures. Expression of several myogenic markers was
induced in p53/;mdm2/ MEFs stimulated to undergo
adipocyte differentiation. This was not the case in p53/
MEFs (Figure 2b). This indicates that Mdm2 might act as a
switch favoring adipogenesis over myogenesis.
Thayer and co-workers21,22 have previously shown that
amplification of the mdm2 gene by microchromosomal
transfer in the C2C12 myoblast cell line abrogates their ability
to undergo myogenesis. We speculated if such C2C12 cells
had increased propensity to undergo adipocyte differentiation.
As expected, C2C12 cells in whichmdm2 had been amplified
(Rh18-11) had increased Mdm2 protein levels compared with
both normal C2C12 and C2C12 cells subjected to micro-
chromosomal transfer of DNA that did not harbor the mdm2
gene (Rh18-3) (Figure 2c). Interestingly, when adipogenesis
was induced in these three cell lines, only Rh18-11 cells
accumulated fat as shown by Oil-Red-O staining and induced
robust expression of adipocyte marker genes (Figures 2d
and e). These data indicate that Mdm2 regulates cellular fate
by promoting adipogenesis at the expense of myogenesis.
Mdm2 is required for the cAMP-mediated induction of
C/EBPd. The inability of rosiglitazone to restore adipogenesis
in MEFs lacking mdm2 indicated that induction of PPARg
expression was perturbed in mdm2-null cells. Unlike in MEFs
only lacking p53, neither PPARg1, PPARg2 nor C/EBPamRNA
levels were increased in p53/;mdm2/ MEFs in response
to MDI and rosiglitazone treatment (Figure 3a). However,
retroviral-mediated restoration of PPARg2 expression was
sufficient to overcome the block in adipocyte differentiation of
p53/;mdm2/ MEFs (Supplementary Figure 2).
When we examined the expression pattern of C/EBPb and
C/EBPd in p53/ and p53/;mdm2/MEFs, we found that
C/EBPb was induced to comparable levels in the two MEF
genotypes, whereas C/EBPd induction was abrogated in
p53/;mdm2/MEFs (Figure 3b). Intriguingly, upregulation
of an immediate-early-induced gene, Krox20, that is required
for adipogenesis and for C/EBPb induction23 wasmore robust
in MEFs lacking mdm2 (Figure 3b). Xanthine oxidoreductase
(XOR) and Kru¨ppel-like factor 5 (KLF5) are induced transi-
ently in a C/EBPb- and C/EBPd-dependent manner, respec-
tively, during adipocyte differentiation.24,25 Consistent with the
expression profiles of the twoC/EBPs, XOR, but not KLF5, the
expression was increased upon induction of differentiation in
p53/;mdm2/ MEFs (Figure 3b). Taken together, these
results indicate that Mdm2 is required for the induction of
C/EBPd, but not C/EBPb during adipogenesis.
To examine whether the failure to induce C/EBPd expres-
sion is causally related to the impaired differentiation of
p53/;mdm2/ MEFs, we transduced p53/;mdm2/
MEFs with a retrovirus expressing C/EBPd. Forced expression
of C/EBPd at least partially restored adipocyte differentiation
(Supplementary Figure 3).
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As the expression of C/EBPd is increased shortly after
induction of differentiation, its expression may be regulated by
individual components of the hormonal cocktail. C/EBPd
expression is normally considered to be induced by Dex both
in preadipocytes and mature adipocytes.26 C/EBPd expres-
sion is, however, also known to be regulated by cAMP during
adipogenesis.27 When treating wild-type MEFs with the
individual components of the adipogenic cocktail, we
observed an increase in C/EBPd expression upon treatment
with Dex or IBMX alone, effects that were additive when both
compounds were included (Figure 3c). Insulin or rosiglitazone
did not affect C/EBPd expression. We observed the same
Figure 1 The N-terminal half of Mdm2 is required for adipogenesis. (a and b) P53/ and p53/;mdm2/ MEFs were induced to undergo adipocyte differentiation
according to the MDI standard protocol in the absence (a) or presence (b) of rosiglitazone. Adipogenesis was assessed by Oil-Red-O staining of triglycerides (top) and
expression of adipocyte marker genes was measured using real-time PCR and shown relative to p53/ MEFs (bottom). (c and d) P53/;mdm2/ MEFs were retrovirally
transduced with empty vector, vector expressing the N-terminal half of Mdm2 (Mdm2 aa1–220) or vector expressing the C-terminal half of Mdm2 (Mdm2 aa 221–491).
Transduced MEFs were induced to undergo adipogenesis according to the MDI standard protocol in the presence of rosiglitazone. Adipocyte differentiation was measured by
Oil-Red-O staining of triglycerides (c) and adipocyte marker gene expression using real-time PCR (d). PEPCK, phosphoenolpyruvate carboxykinase. (e) P53H/H (n¼ 4) and
p53H/H;mdm2/ (n¼ 5) mice were subjected to CT scanning. Volumes of total adipose, bone and soft tissue in general were scored. Error bars represent S.E.M.
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pattern of C/EBPd induction in 3T3-L1 cells (data not shown),
showing that cAMP contributes to the induction of C/EBPd
expression at the onset of adipocyte differentiation.
We have recently shown that the adipogenic effect of
elevated cAMP levels relies on the activation of both protein
kinase A (PKA) and the exchange protein activated by cAMP
(Epac).28 Using selective activators of both PKA andEpac, we
show that only the PKA activator augmented expression of
C/EBPd (Figure 3d).
As p53/;mdm2/ failed to increase C/EBPdmRNA levels
at the onset of adipogenesis, we speculated that this could be
attributed to a failure to respond to either Dex or IBMX. As in
wild-type MEFs, treating p53/ MEFs with Dex, IBMX or a
combination led to an induction of C/EBPd expression. By
contrast, treatment withDex, but not IBMX, induced expression
of C/EBPd in p53/;mdm2/MEFs (Supplementary Figure 4).
To ensure that the induction of C/EBPd was an early effect
downstream of elevated cAMP levels, C/EBPd expression was
measured 1h after the addition of vehicle, IBMX or another
cAMP-elevating compound, forskolin. In contrast to their effect
in p53/ MEFs, addition of IBMX or forskolin to p53/;
mdm2/ MEFs failed to increase C/EBPd mRNA levels
(Figure 3e).
IBMX elevates the level of cAMP by inhibiting cAMP-
degrading phosphodiesterases. The recent association of
Mdm2 with phosphodiesterase degradation29 raised the
possibility that IBMX treatment resulted in different levels of
cAMP in p53/ and p53/;mdm2/ MEFs. Contrary to this
possibility, we found that MEFs of both genotypes had equal
levels of cAMP both before and after IBMX stimulation
(Supplementary Figure 5). Collectively, these data suggest
that Mdm2 is required for adipogenesis in a manner related to
cAMP signaling.
Mdm2 is required for CREB activation. C/EBPd was
recently suggested to be a putative CREB-regulated gene
in a global screen for CREB target genes.30 The canonical
transcriptional pathway downstream of PKA activation is
mediated by direct serine-133 phosphorylation of CREB.
In addition to PKA, several other kinases can also activate
CREB by phosphorylating serine 133. In fact, it is the
mitogen-activated protein kinase (MAPK) that is responsible
for CREB phosphorylation during the initiation of adipocyte
differentiation.28 An important function of PKA during adipose
conversion is inhibition of the Rho kinase28 that in turn can
inhibit adipogenesis by blocking the MAPK-mediated
phosphorylation of CREB.31 To ensure that the failure to
induce C/EBPd in the absence of Mdm2 was not a result of
uncontrolled Rho-kinase activity, we concomitantly treated
the p53/;mdm2/ MEFs with IBMX and increasing doses
of a Rho-kinase inhibitor. The inhibitor failed to restore IBMX-
mediated induction of C/EBPd in p53/;mdm2/ MEFs
(Supplementary Figure 6). In further support of normal Rho-
kinase activity in the absence of Mdm2, we observed no
differences in serine 133 phosphorylation of CREB in p53/
and p53/;mdm2/ MEFs upon induction of adipogenesis
(Supplementary Figure 7).
Figure 2 Mdm2 favors adipogenesis over myogenesis. (a) Myotube resemblance of p53/;mdm2/ MEFs induced to undergo adipogenesis. P53/;mdm2/ MEFs
were induced to undergo adipocyte differentiation according to the standard MDI protocol and supplemented with rosiglitazone:  400 magnification of p53/;mdm2/
MEFs with myotube resemblance. (b) Expression of myocyte marker genes in p53/ and p53/;mdm2/ MEFs before and 10 days after induction of adipogenesis. Myh1
(myosin heavy chain 1), MyoD (myogenic differentiation), Myf6 (myogenic factor 6). (c) Western blot analysis of Mdm2 protein levels in C2C12, Rh18-3 and Rh18-11 at
confluence. TFIIB was included as a loading control. (d and e) C2C12, Rh18-3 and Rh18-11 cells were induced to undergo adipogenesis according to the MDI standard
protocols in the presence of rosiglitazone. Adipogenesis was scored by Oil-Red-O staining (d) and adipocyte marker gene expression (e). FAS, fatty acid synthase;
HSL, hormone-sensitive lipase
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Although CREB phosphorylation was comparable in MEFs
of both genotypes, the induction of several cAMP-responsive
CREB target genes8,30 was perturbed in p53/;mdm2/
MEFs upon IBMX treatment (Figure 4a). We therefore
speculated whether Mdm2 could be a direct modulator of
CREB activity. We measured the transcriptional activity of
CREB fused to the GAL4 DNA-binding domain in the absence
and presence of increasing levels of Mdm2 in p53/;mdm2/
MEFs. As shown in Figure 4b, Mdm2 enhanced the activity of
the fusion protein markedly in the presence of forskolin.
CREB is not only activated by elevated cAMP levels, but
also by several growth factors, hormones and by stress
signals. A commonly used stress activator of CREB is the
phorbol ester TPA/PMA (phorbol 12-myristate 13-acetate).
cAMP and TPA elicit two distinct transcriptional programs
through CREB.9 To examine if the requirement for Mdm2 in
CREB-dependent transactivation was restricted to cAMP-
mediated activation, we treated p53/ and p53/;mdm2/
MEFs with vehicle or TPA. As shown in Figure 4c, TPA
administration failed to induce the expression of examined
CREB target genes in p53/;mdm2/ MEFs. Collectively,
these data suggest that Mdm2 is required for the activation of
CREB in response to both stress and cAMP-elevating stimuli.
Mdm2 is required for recruitment of Crtc2/TORC2 to the
c/ebpd promoter. A family of transcriptional cofactors,
denoted as CREB-regulated transcription coactivator
(Crtcs or TORCs), has recently been implicated in the
cAMP-mediated response of CREB. The Crtcs solely
coactivate CREB bound to genes regulated by cAMP9 by
facilitating the recruitment of the two histone acetylases p300
and CBP to CREB.8,9
Under basal conditions, Crtc is localized to the cytoplasm as
a result of a phosphorylation-dependent interaction with 14-3-3
proteins, mediated by members of the salt-inducible kinase
(SIK) family. Upon elevated cAMP levels, PKA inhibits the
SIKs, leading to dephosphorylation and translocation of Crtc
to the nucleus and subsequent coactivation of CREB.7
If Crtcs are involved in the induction of C/EBPd expression,
repression of SIK should lead to an increase in the C/EBPd
Figure 3 Mdm2 is required for cAMP-mediated induction of C/EBPd. (a and b) P53/ and p53/;mdm2/ MEFs were induced to undergo adipogenesis according to
the MDI standard protocol in the presence of rosiglitazone. mRNA levels of Krox20, C/EBPs, PPARg, XOR and KLF5 were assessed using real-time PCR. (c) Wild-type MEFs
were treated with Dex, IBMX, insulin or rosiglitazone. Expression of C/EBPd was scored 24 h later using real-time PCR. (d) Wild-type MEFs were treated for 24 h with vehicle,
PKA activator, Epac activator or both. mRNA levels of C/EBPd were measured using real-time PCR. (e) P53/ and p53/;mdm2/ MEFs were treated with either vehicle,
IBMX or forskolin for 1 h. Expression of C/EBPd was assessed using real-time PCR
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mRNA level. Although there is no specific chemical inhibitor of
SIK, the general kinase inhibitor staurosporine has been used
as it inhibits SIK at low concentrations.32 We show that while
staurosporine induced C/EBPd expression in p53/MEFs, it
did not change the level of C/EBPdmRNA in p53/;mdm2/
MEFs (Figure 5a).
The involvement of Crtc in regulating cAMP-mediated
induction of C/EBPd expression was underscored by the
finding that ectopic expression of a dominant-negative
Crtc (DN-Crtc) lowered the induction of C/EBPd and other
CREB target genes in p53/ MEFs upon IBMX treatment
(Figure 5b). Furthermore, ectopic expression of the DN-Crtc
lowered the adipogenic potential of p53/MEFs as assessed
by adipocyte marker gene expression (Figure 5c).
Of the three Crtcs, Crtc2 is the best described and has been
reported to be expressed in adipose tissue.33 We therefore
examined if Mdm2 could interact directly with Crtc2. Using
GST pull down, we were able to pull down in vitro translated
Crtc2 with GST-Mdm2, but not with GST alone (Figure 5d).
Interestingly, Crtc2 was able to interact separately with the
two halves of Mdm2 albeit with lower affinity than full-length
Mdm2 (Figure 5d).
The N-terminal half of Mdm2 harbor the nuclear localiza-
tion and export signals. As the Crtcs are imported into the
nucleus upon cAMP stimulation, we speculated if Mdm2 was
required for this translocation. However, GFP-tagged Crtc2
localized to the nucleus upon cAMP stimulation in both p53/
and p53/;mdm2/ MEFs (Supplementary Figure 8),
arguing that Mdm2 is dispensable for the nucleic import
of Crtc2.
The TFSearch program34 revealed the presence of two
putative CREs in the 5 kb region upstream of the transcrip-
tional start site of themurine c/ebpd promoter (Supplementary
Figure 9). Both elements deviate from the consensus at only
one position. We found no putative CREs within or 5 kb
downstream of the murine c/ebpd gene. In contrast to mice,
humans have four putative CREs within the 5 kb region
upstream of the transcriptional start site.
Using chromatin immunoprecipitation (ChIP), we assessed
differences in the recruitment of the active CREB transcriptional
complex in response to increased cAMP levels. Phosphory-
lated CREB was recruited to the proximal CRE (CRE2) relative
to the transcriptional start site in the c/ebpd promoter upon
IBMX treatment (Figure 5e). Interestingly, Mdm2 was required
for the recruitment of Crtc2 to the same CRE. The inability to
form a transcriptional active complex on the c/ebpd promoter in
the absence of Mdm2 was underscored by the finding that in
contrast to p53/MEFs, binding of the two histone acetylases
p300 and CBP was not increased in p53/;mdm2/ MEFs
upon IBMX treatment. Western blotting showed equal levels of
P-CREB, Crtc2, p300 and CBP in p53/ and p53/;mdm2/
MEFs (Supplementary Figure 10).
Collectively, these data indicate that Mdm2 is required for
CREB-mediated induction of C/EBPd by facilitating the
assembly of the transcriptional complex consisting of CREB,
Crtc2 and p300/CBP on the c/ebpd promoter.
Figure 4 Mdm2 augments the activity of CREB. (a) P53/ and p53/;mdm2/ MEFs were treated with IBMX for 4 h. mRNA levels were measured using real-time
PCR. Areg, amphiregulin; CREM, cAMP-response element modulator; Dusp1, dual-specificity phosphatase 1; Hlf, hepatic leukemia factor. (b) P53/;mdm2/ MEFs were
transfected with UAS-GAL luciferase reporter plasmid, CMV-b-galactosidase reporter plasmid, GAL4-CREB and increasing levels of a vector expressing Mdm2. Cells were
treated overnight with vehicle or forskolin. Luciferase activity was normalized to b-galactosidase measurements. (c) P53/ and p53/;mdm2/ MEFs were treated with
TPA for 1 h. mRNA levels were measured using real-time PCR
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Discussion
The transcription factor CREB plays a key role in adipocyte
differentiation.4–6 Our results show that Mdm2 enhances
CREB activity and adipocyte differentiation by facilitating the
recruitment of Crtc2 and p300/CBP to CREB bound to the
c/ebpd promoter. Conversely, MEFs lacking mdm2 fail to
undergo adipocyte differentiation.
Our ex vivo data revealed a striking dependency on Mdm2
for adipocyte differentiation by facilitating the induction of
C/EBPd. However, CT scans of mice harboring and lacking
Mdm2 revealed no statistically significant difference in total
adipose tissue (P¼ 0.08). In their analyses of mice lacking
C/EBPd, C/EBPb or both, Akira and co-workers2 did not
observe a decreased weight of adipose tissue in mice lacking
either C/EBPd or C/EBPb. Only mice lacking both C/EBPs
had a significant decrease in adipose mass. It is therefore
conceivable that C/EBPd is dispensable for adipogenesis in
mice lackingMdm2, and that C/EBPb, the expression of which
is unaffected by the absence of Mdm2, is sufficient to support
adipogenesis in vivo.
Given the importance of Crtc2 in regulating a distinct
transcriptional program through CREB downstream of cAMP
stimulation, the modes of regulating the activity of the cofactor
have been an area of intense research.
In resting cells, Crtc2 is localized to the cytoplasm. Upon
cAMP stimulation Crtc2 translocates to the nucleus.7 We
observed no difference in the ability to translocate exogen-
ously expressed Crtc2 in p53/ and p53/;mdm2/ MEFs
upon cAMP elevation, arguing for normal translocation of
Crtc2 in the absence of Mdm2.
Activation of Crtc2 is controlled by several serine phosphor-
ylations, all exerting an inhibitory function on Crtc2 by either
decreasing its coactivator activity or ablating nuclear transloca-
tion.35 These phosphorylations can all be removed by treating
cells with the general kinase inhibitor, staurosporine.35 Intrigu-
ingly, although staurosporine was able to induce C/EBPd
expression in p53/, the inhibitor was unable to induce
C/EBPd expression in p53/;mdm2/MEFs. This demon-
strates that even removal of inhibitory phosphorylations on Crtc2
was unable to restore C/EBPd induction in p53/;mdm2/
MEFs. Furthermore, IBMX treatment lead to disappearance of
the upper, phosphorylated band in western blots of Crtc2 in
MEFs of both genotypes (Supplementary Figures 10 and 11),
demonstrating that deficient IBMX-mediated dephosphorylation
was not the cause of abated Crtc2 activation upon cAMP
stimulation in mdm2-deficient MEFs.
As Mdm2 is an ubiquitin ligase and regulates the stability of,
for example, p53, it is of interest that the stability of Crtc2 has
been reported to be regulated by ubiquitination.36 However,
Figure 5 Mdm2 is required for the recruitment of Crtc2 and p300/CBP to CREs in the c/ebpd promoter. (a) P53/ and p53/;mdm2/ MEFs were treated with vehicle
or staurosporine for 4 h. C/EBPd mRNA levels were measured using real-time PCR. (b and c) P53/ MEFs were retrovirally transduced with vector expressing GFP or GFP-
DN-Crtc. (b) Transduced MEFs were treated with vehicle or IBMX for 1 h. mRNA levels were determined using real-time PCR. (c) Transduced MEFs were induced to undergo
adipogenesis according to the MDI standard protocol in the presence of rosiglitazone. Adipocyte differentiation was scored by adipocyte marker gene expression. GLUT4,
glucose transporter 4. (d) In vitro translated Crtc2 was pulled down using Mdm2 or its halves fused to GST. (e) At 2 days postconfluence, p53/ and p53/;mdm2/ MEFs
were left untreated or stimulated with IBMX for 30 min. Binding of P-CREB, Crtc2, p300 and CBP to the c/ebpd promoter was assessed by chromatin immunoprecipitation.
Non-specific IgG was included as control. b-Globin was used to assess background levels
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both the level and stability of Crtc2 were similar in p53/ and
p53/;mdm2/ MEFs (Supplementary Figure 11).
Interestingly, the activity of Crtc2 is augmented by a p300-
mediated acetylation.36 Given our demonstration that Mdm2
can directly interact with Crtc2, and previous evidence that it
can also interact with p300/CBP,37 it is possible that Mdm2
serves as a scaffold for the interaction between p300/CBP
andCrtc2 and thereby facilitates the acetylation and activation
of the latter. Although both the C- and the N-terminal halves of
Mdm2 can interact with Crtc2, the ability of the N-terminal part
of Mdm2 to restore adipogenesis might reflect the potential of
this half of Mdm2 to also bind p300/CBP.37
Besides the involvement of Mdm2 in the cAMP-stimulated
activation of CREB, Mdm2 is also required for in stress-
mediated stimulation of CREB. This was shown by the
impaired induction of CREB-responsive genes in cells lacking
Mdm2 after TPA treatment. As TPA-mediated activation of
CREB is independent of Crtc2 recruitment, it is most likely that
Mdm2 regulates CREB downstream of stress signals through
a distinct mechanism.
Our data point to a p53-independent requirement of Mdm2
for adipocyte differentiation. Given the important role of Mdm2
in regulating p53 activity and the recently shown inhibitory
effect of p53 on adipogenesis,38 it is conceivable that Mdm2
exerts dual functions in relation to the regulation of adipocyte
differentiation. Mdm2 could theoretically augment adipogen-
esis through potentiating of CREB-mediated transactivation
and restriction of p53 activity. Further studies are required to
determine the relative contribution of Mdm2 to these two
functions. This could be assessed by comparing adipogenesis
inwild-type and p53-deficientMEFs deficient forMdm2 through
Cre-mediated deletion of floxed-Mdm2 alleles or lowered
expression through siRNA-mediated knockdown of Mdm2.
Earlier studies have shown that increased levels of Mdm2
block myocyte differentiation due to inhibition of Sp1 activity.21,22
Here, we show thatMdm2 favors the differentiation of adipocytes
at the expense of myogenesis. As myocytes and adipocytes
originate from MSCs, it is possible that Mdm2 is involved in the
determination of cell fate of MSCs, a notion underscored by the
consistent amplification of Mdm2 in liposarcomas.
Materials and Methods
Cell culture and differentiation. Wild-type MEFs were a generous gift from
Dr. Jiri Bartek. P53/ and p53/;mdm2/ MEFs have been described
previously.39 MEFs were grown in AmnioMax basal medium (Invitrogen, Carlsbad,
CA, USA) supplemented with 7.5% fetal bovine serum, 7.5% AmnioMax-C100
supplement (Invitrogen), 2 mM glutamine, 62.5mg/ml penicillin and 100mg/ml
streptomycin (Lonza, Basel, Switzerland). The medium was changed every second
day. For differentiation, 2-day postconfluent cells (day 0) were treated with growth
medium containing 1 mM Dex (Cat. no. D1756), 0.5 mM IBMX (Cat. no. I7018),
1mg/ml Ins (Cat. no. I6634) (all Sigma-Aldrich, St. Louis, MO, USA). From days 2 to
4, the medium contained Ins. Rosiglitazone (0.5mM) (Cat no. 71740; Cayman,
Ann Arbor, MI, USA) or vehicle (DMSO) (Cat no. D8418; Sigma-Aldrich) was added
throughout differentiation. Forskolin (10 mM) (Cat. no. F3917) and TPA/PMA
(20 nM) (Cat. no. P1585) were from Sigma-Aldrich; staurosporine (10 nM) (Cat. no.
S-9300) from LC Laboratories (Woburn, MA, USA); Rho kinase inhibitor (10 mM)
(Cat. no. 555550) from Calbiochem (San Diego, CA, USA); and specific PKA
(100mM) (Cat. no. M 003) and Epac (200mM) (Cat. no. C 041) activators were from
Biolog (Hayward, CA, USA). Cycloheximide (Cat. no. O1810; Sigma-Aldrich) was
used in a concentration of 15mg/ml.
Retroviral transduction. Phoenix cells were transfected with pBABE-based
plasmids. At 2 days post-transfection, media were isolated, spun down at 1200 g
for 5 min to remove cellular debris, mixed 1 : 1 with standard media and added to
cells. Polybrene was added to a final concentration of 6mg/ml. Cells were selected
for 2 days using puromycin (3 mg/ml).
Chromatin immunoprecipitation. ChIP was carried out essentially as
described previously,40 except that crosslinking was carried out by adding
formaldehyde directly to the media to a final concentration of 1%, followed by
incubation at 371C for 20 min. Furthermore, 48 rounds of sonication were applied.
Finally, DNA was purified by phenol–chloroform extraction. Antibodies used were
P-CREB-1 (Ser133) (sc-7978), CBP (sc-369), p300 (sc-584) and Crtc2 (sc-46272) (all
from Santa Cruz Technology, Santa Cruz, CA, USA). Primer sequences are CRE1,
50-GTTCAGCTTCTGTGTTTAGAGG-30 and 50-CCCTCTCCTTCTGCTCCTCC-30;
CRE2, 50-GCTGCGGAGCCTTGATCC-30 and 50-CACTCCTTGCCTTCCCTCC-30;
and b-globin, 50-CCTGCCCTCTCTATCCTGTG-30 and 50-GCAAATGTGTTG
CCAAAAAG-30.
RNA purification, reverse transcription and real-time PCR. RNA
was purified using TRIzol (Invitrogen) according to the manufacturer’s instructions.
Reverse transcription was performed essentially as described elsewhere.41
Quantitative PCR was performed in 20ml reactions containing SYBR Green
JumpStart Taq ReadyMix (Sigma-Aldrich), 1.5ml of diluted cDNA and 300 nM of
each primer. Reaction mixtures were preheated at 941C for 2 min, followed
by 40 cycles of melting at 941C for 15 s, annealing at 601C for 30 s and elongation
at 721C for 45 s. Reactions were ran on a Stratagene MX3000P and quantified
using Stratagene MxPro. Primer sequences are included in supporting Materials
and Methods.
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